FHTX Stock Overview
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Foghorn Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.39 |
| 52 Week High | US$9.97 |
| 52 Week Low | US$2.70 |
| Beta | 3.13 |
| 1 Month Change | 7.76% |
| 3 Month Change | 52.14% |
| 1 Year Change | -10.38% |
| 3 Year Change | -46.66% |
| 5 Year Change | n/a |
| Change since IPO | -64.74% |
Recent News & Updates
Recent updates
Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth
Apr 12
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too
Feb 22Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth
Dec 13Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues
Nov 07Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
Jun 14Foghorn Therapeutics: Selling For Less Than Cash Value
Oct 10Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286
Aug 23Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M
Aug 09Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
Jun 02We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely
Apr 13Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
Feb 27Shareholder Returns
| FHTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.0% | -5.0% | -3.5% |
| 1Y | -10.4% | -1.7% | 20.2% |
Return vs Industry: FHTX underperformed the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: FHTX underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| FHTX volatility | |
|---|---|
| FHTX Average Weekly Movement | 24.2% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FHTX's share price has been volatile over the past 3 months.
Volatility Over Time: FHTX's weekly volatility has increased from 16% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 116 | Adrian H. Gottschalk | foghorntx.com |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome.
Foghorn Therapeutics Inc. Fundamentals Summary
| FHTX fundamental statistics | |
|---|---|
| Market cap | US$256.67m |
| Earnings (TTM) | -US$98.43m |
| Revenue (TTM) | US$34.16m |
8.0x
P/S Ratio-2.8x
P/E RatioIs FHTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FHTX income statement (TTM) | |
|---|---|
| Revenue | US$34.16m |
| Cost of Revenue | US$109.69m |
| Gross Profit | -US$75.53m |
| Other Expenses | US$22.89m |
| Earnings | -US$98.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.31 |
| Gross Margin | -221.15% |
| Net Profit Margin | -288.17% |
| Debt/Equity Ratio | 0% |
How did FHTX perform over the long term?
See historical performance and comparison